gip/glp 1-agonist tirzepatide Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Tirzepatide 10mg — Dual Receptor

Our study also found that, in general, patients without type 2 diabetes experienced greater weight loss than patients with type 2 diabetes, but tirzepatide was more effective than semaglutide in both groups. Study author Nick Stucky, MD, PhD, vice president of Truveta Research and practicing infectious disease physician with Providence Portland Medical Center, noted the following about the study to Medical News Today: While tirzepatide was significantly more effective than semaglutide, patients on both medications experienced substantial weight loss and we observed no difference in the risk of GI adverse events. In addition to effectiveness, factors like medication availability and insurance coverage will likely play a role in deciding which medication to initiate

As a GLP-1 receptor agonist , tirzepatide stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it only promotes insulin release when blood glucose levels are elevated

This medication helps to improve blood sugar control by stimulating insulin production and reducing glucose in the liver

Blacher, E

Amendments were documented in updated study protocols available on ClinicalTrials.gov